<DOC>
	<DOCNO>NCT02533427</DOCNO>
	<brief_summary>This study evaluate effect sofosbuvir ( SOF ) /velpatasvir ( VEL ) /GS-9857 fixed-dose combination ( FDC ) + GS-9857 pharmacokinetics ( PK ) representative hormonal contraceptive medication , norgestimate/ethinyl estradiol ( Ortho Tri-Cyclen® Lo ( OC ) ) ass effect norgestimate/ethinyl estradiol PK SOF/VEL/GS-9857+GS-9857 .</brief_summary>
	<brief_title>Effect Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination Pharmacokinetics Representative Hormonal Contraceptive Medication , Norgestimate/Ethinyl Estradiol</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal female Must calculate BMI ≥ 19.0 ≤ 30.0 kg/m^2 screening Must negative serum pregnancy test screen urine pregnancy test Day 1 Be willing able comply study requirement . Lactating female Have history follow : Significant drug sensitivity drug allergy ( anaphylaxis hepatoxicity ) Known hypersensitivity study drug , metabolite formulation excipients Believed , study investigator , inappropriate study participation reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>